-

$undefined

N/A

(N/A)

Akero Therapeutics NASDAQ:AKRO Akero Therapeutics is a clinical-stage cardio-metabolic company developing transformational treatments for non-alcoholic steatohepatitis (NASH), a disease without any approved therapies. Akero's lead product candidate, EFX, an engineered Fc-FGF21 fusion protein, is currently being evaluated in Phase 2 clinical trials as a potential treatment for NASH. Akero is headquartered in South San Francisco.

Location: 601 Gateway Boulevard, Suite 350, California, 94080, United States | Website: www.akerotx.com | Industry: Pharmaceutical Preparation Manufacturing | Sector: Manufacturing

Market Cap

NaN

52 Wk Range

$ - $

Previous Close

$N/A

Open

$N/A

Day Range

N/A - N/A

Volume

N/A

Avg Volume

N/A

Enterprise Value

2.87B

Cash

743.1M

Avg Qtr Burn

-57.53M

Short % of Float

9.50%

Insider Ownership

2.08%

Institutional Own.

95.13%

Qtr Updated

12/31/24

Drug Pipeline

Powered by

Only showing assets and stage. See catalyst data with a free or premium account. Unlock more data with a free account.

Drug & Indication	Stage & Event	Catalyst Date
Efruxifermin (FGF-21 mimetic) Details Compensated cirrhosis (F4) due to MASH	Phase 3 Data readout	Some catalyst date You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details.Sign up now.
Efruxifermin (FGF-21 mimetic) Details Pre-cirrhotic MASH with fibrosis stages F2–F3, Non-invasively diagnosed MASLD (F1–F4 fibrosis)	Phase 3 Data readout	Some catalyst date You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details.Sign up now.
Efruxifermin (FGF-21 mimetic) Details Compensated cirrhosis (F4, Child-Pugh A) due to MASH	Phase 2b Update	Some catalyst date You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details.Sign up now.
Efruxifermin (FGF-21 mimetic) Details Pre-cirrhotic MASH with fibrosis stages F2–F3	Phase 2b Update	Some catalyst date You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details.Sign up now.